NCT07566156
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07566156
Title Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )
Acronym EV-309
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Samsun Clinic - Ridley-Tree Cancer Center RECRUITING Santa Barbara California 93105 United States Details
Medical Oncology Hematology Consultants RECRUITING Newark Delaware 19713 United States Details
Illinois Cancer Specialists RECRUITING Niles Illinois 60714 United States Details
Fort Wayne Medical Oncology and Hematology RECRUITING Fort Wayne Indiana 46825 United States Details
Missouri Cancer Associates RECRUITING Columbia Missouri 65201 United States Details
Williamette Valley Cancer Institute and Research Center RECRUITING Eugene Oregon 97401 United States Details
Compass Oncology - West RECRUITING Tigard Oregon 97223 United States Details
SCRI Oncology Partners RECRUITING Nashville Tennessee 37203 United States Details
Texas Oncology RECRUITING Austin Texas 78705 United States Details
Texas Oncology - Northeast Texas RECRUITING Tyler Texas 75702 United States Details
Virginia Oncology Associates RECRUITING Norfolk Virginia 23502 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field